BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [1] Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis
    Dabal, Tracey D.
    Haltom, Matthew B.
    Patel, Puja P.
    Son, Christine K.
    Joglekar, Kiran P.
    Groeschell, Charles M.
    Chumpia, Mason M.
    Kamal, Sehrish F.
    Seth, Ankur
    Jackson, Christopher D.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (05) : 288 - 292
  • [2] Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance
    Takagi, Michiaki
    Atsumi, Tatsuya
    Matsuno, Hiroaki
    Tamura, Naoto
    Fujii, Takao
    Okamoto, Nami
    Takahashi, Nobunori
    Nakajima, Atsuo
    Nakajima, Ayako
    Tsujimoto, Naoto
    Nishikawa, Atsushi
    Ishii, Taeko
    Takeuchi, Tsutomu
    Kuwana, Masataka
    MODERN RHEUMATOLOGY, 2023, 33 (04) : 647 - 656
  • [3] Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study
    Kameda, Hideto
    Nishida, Keiichiro
    Nanki, Toshihiro
    Watanabe, Akira
    Oshima, Yukiya
    Momohara, Shigeki
    MODERN RHEUMATOLOGY, 2023, 33 (03) : 460 - 471
  • [4] Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials
    Chen, Ying-Chou
    Yoo, Dae Hyun
    Lee, Chang Keun
    Li, Ko-Jen
    Won, Ji-Eon
    Wu, Wen-Shuo
    Zhong, Jinglin
    Nicolay, Claudia
    Walls, Chad Daniel
    Tanaka, Yoshiya
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (01) : 65 - 73
  • [5] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    RHEUMATOLOGY, 2021, 60 (05) : 2256 - 2266
  • [6] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study
    Caporali, Roberto
    Taylor, Peter C.
    Aletaha, Daniel
    Sanmarti, Raimon
    Takeuchi, Tsutomu
    Mo, Daojun
    Haladyj, Ewa
    Bello, Natalia
    Zaremba-Pechmann, Liliana
    Fang, Ying
    Dougados, Maxime
    RHEUMATOLOGY, 2024, 63 (10) : 2799 - 2809
  • [7] Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
    Smolen, Josef S.
    Genovese, Mark C.
    Takeuchi, Tsutomu
    Hyslop, David L.
    Macias, William L.
    Rooney, Terence
    Chen, Lei
    Dickson, Christina L.
    Camp, Jennifer Riddle
    Cardillo, Tracy E.
    Ishii, Taeko
    Winthrop, Kevin L.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (01) : 7 - 18
  • [8] Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
    Jonathan Kay
    Janusz Jaworski
    Rafal Wojciechowski
    Piotr Wiland
    Anna Dudek
    Marek Krogulec
    Slawomir Jeka
    Agnieszka Zielinska
    Jakub Trefler
    Katarzyna Bartnicka-Maslowska
    Magdalena Krajewska-Wlodarczyk
    Piotr A. Klimiuk
    Sang Joon Lee
    Yun Ju Bae
    Go Eun Yang
    Jae Kyoung Yoo
    Daniel E. Furst
    Edward Keystone
    Arthritis Research & Therapy, 23
  • [9] Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
    Kay, Jonathan
    Jaworski, Janusz
    Wojciechowski, Rafal
    Wiland, Piotr
    Dudek, Anna
    Krogulec, Marek
    Jeka, Slawomir
    Zielinska, Agnieszka
    Trefler, Jakub
    Bartnicka-Maslowska, Katarzyna
    Krajewska-Wlodarczyk, Magdalena
    Klimiuk, Piotr A.
    Lee, Sang Joon
    Bae, Yun Ju
    Yang, Go Eun
    Yoo, Jae Kyoung
    Furst, Daniel E.
    Keystone, Edward
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [10] BARISUR STUDY: DESCRIPTIVE STUDY OF BARICITINIB SAFETY IN SPANISH PATIENTS WITH RHEUMATOID ARTHRITIS
    Rubio Romero, E.
    Gallego, A.
    Llanes, M.
    Delgado Vidal, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 736 - 736
12345